Mursla
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
181 Cambridge Science Park, Cambridge, C...Phone Number
+44 1223928141Website
www.mursla.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Mursla
Mursla Bio specializes in AI Precision Medicine and Diagnostics, focusing on the analysis of organ-specific extracellular vesicles from blood. Their flagship product, EvoLiver, is a blood test designed to detect liver cancer early in high-risk populations with cirrhosis, recently receiving FDA Breakthrough Device Designation. The company targets high-risk cancer populations, particularly those with pre-existing liver conditions, to improve early detection rates. Mursla Bio's proprietary AI Precision Medicine Platform enhances biomarker discovery and supports clinical deployment of diagnostic assays.Explore more
Mursla Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mursla your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Mursla, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Mursla has recently received funding, and reach out quickly before it becomes old news!
Click to see if Mursla had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Mursla has new funding data
Check out if Mursla is spiking on competitors!
Earning: See what the market has to say on Mursla recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Mursla launches new products
Congratulate Masked Content for being promoted to Masked Content at Mursla
Recommended Actions
Reach out to Masked Content who joined Mursla as Masked Content
Find more new buyers
Compare Similar Companies to Mursla
Compare insights from companies similar to Mursla, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mursla is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Mursla is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Mursla.
Mursla Tech Stack
A closer look at the technologies used by Mursla
See more technologies
Most Recent Scoops
New Hire
Executive Move
Funding
Funding
Funding
Mursla News & Media
Mursla Bio Receives FDA Breakthrough Device Designation for EvoLiver Test
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead product, EvoLiver™. The designation recognizes the potential of the Company’s Dynamic Biopsy-based blood test, EvoLiver, which is enabled by a novel plMursla Bio’s EvoLiver Surpasses Current Standards in Liver Cancer Surveillance, Data Presented at AASLD Liver Meeting 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-centre clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz. The ongoing study isMursla Bio Joins Leading European Consortium to Advance Clinical Applications Based on Extracellular Vesicle Science
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, announced it has been invited to join EVEREST, a leading European consortium. The consortium’s objective is to advance EV research, innovation and clinical translation for the benefit of patients. Mursla Bio’s selection demonstrates the Company’s leadership in the field,Mursla Bio Presents Breakthrough Liquid Biopsy Technology for Extracellular Vesicles in Cell Press
CAMBRIDGE, England--(BUSINESS WIRE)-- #Cambridge--Mursla Bio’s breakthrough technology for the analysis of extracellular vesicles (EV) sub-types within biofluids such as blood showcased in iScience.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Mursla
Sign Up For FreeTo access detailed company insights
Mursla Bio specializes in AI Precision Medicine and Diagnostics, focusing on the analysis of organ-specific extracellular vesicles from blood. Their flagship product, EvoLiver, is a blood test designed to detect liver cancer early in high-risk populations with cirrhosis, recently receiving FDA Breakthrough Device Designation. The company targets hi... Read More
